Tag Archives: finance

Investor Panels at RESI London December 2025 

23 Sep

By Momo Yamamoto, Senior Investor Research Analyst, LSN

RESI London returns on December 4, 2025, at the King’s Fund, 11 Cavendish Square, as part of the UK’s largest life science partnering and venture week. Organized by Life Science Nation, RESI (Redefining Every Stage of Investment) brings together early-stage life science and healthcare innovators with hundreds of global investors and strategic partners for a full day of partnering, networking, educational content, and exhibits. Virtual partnering will continue on December 8–9, extending the opportunity to build new relationships.

A highlight of every RESI conference is the investor panel programming, where active investors and strategic partners share candid insights with entrepreneurs on what they look for, how they invest, and how startups can best position themselves for success. This year’s London panels will provide in-depth discussions across some of the most dynamic and fast-growing areas of healthcare innovation.

Partnering with Big Pharma

Building Strategic Relationships to Accelerate Innovation

Securing a Big Pharma partnership can be transformative for early-stage companies. Leaders from major pharmaceutical business development and venture teams will share how they evaluate early partnerships, what they seek in collaborators, and how startups can stand out in a competitive field.

Angels & Family Offices

Flexible Capital and Long-Term Support for Early-Stage Innovators

Family offices and angel investors are increasingly active in healthcare, often bringing patient capital and a long-term perspective. Panelists will discuss what differentiates them from institutional investors, the types of opportunities they prioritize, and how founders can approach these funders successfully.

Medical Devices & Diagnostics

Forward Looking Trends in MedTech Innovations

The medtech sector continues to evolve rapidly, with new technologies driving precision care, digital integration, and improved patient outcomes. Investors in this session will share their outlook on the most exciting innovations, challenges to commercialization, and what makes a device or diagnostic investment-ready.

Digital Health & AI

Harnessing Technology to Transform the Patient Journey

Digital health and AI solutions are reshaping care delivery and patient engagement. This panel will highlight what excites investors most in digital platforms, data-driven technologies, and AI applications—and the key factors that determine which companies will succeed in this fast-moving space.

UK / Europe Ecosystem

Global Opportunities in a Dynamic Innovation Landscape

London and the broader UK/European ecosystem offer unique opportunities for entrepreneurs and investors alike. This panel will feature funders with deep experience across these markets, discussing emerging trends, cross-border deal-making, and strategies for startups seeking to expand globally.

Early Stage Therapeutics

Accelerating Breakthrough Therapies in Pre-Clinical and Early Clinical Stages

Developing therapeutics in early clinical phases presents both great promise and high risk. Investors in this session will share how they assess early-stage science, key milestones that de-risk programs, and where they see the next wave of transformative therapies emerging.

Seed Funds

Catalyzing the Earliest Stages of Healthcare Innovation

Seed funds are critical to getting transformative ideas off the ground. This panel will explore how seed-stage investors evaluate opportunities, balance risk and return, and support entrepreneurs through their first fundraising rounds.

Whether you are developing therapeutics, devices, diagnostics, or digital health technologies, the RESI London investor panels offer a rare opportunity to hear directly from the investors shaping the future of healthcare.

New this year: A combi ticket option is available for RESI London + Genesis 2025, giving you access to both partnering events in one streamlined package. Save £300 with Super Early Bird rates available until October 3.

Register for RESI London >>

Tags: , , , , ,

Hot Investor Mandate: China-Based PE Firm Invests in Various Life Science Sectors, Investing $5-50M from Series A through Pre-IPO in US, Europe, and China

9 Sep

 A China-based private equity firm affiliated with a global investment group has raised multiple funds to date and invests across multiple sectors, including healthcare. The firm is a full-spectrum investor, participating from Series A through pre-IPO and PIPE, and may also consider buyouts and add-on acquisitions for its portfolio. Typical investments range from $5-50M, with the capacity to commit up to $100M per company. While the firm is primarily focused on opportunities in China, it also invests in companies from the US and Europe that present a strong China angle. 

The firm invests opportunistically in the healthcare sector on a case-by-case basis. Areas of interest include biopharma, medical devices and equipment, diagnostics, healthcare IT, and R&D services with significant market potential. The firm is stage-agnostic and will consider products ranging from pre-clinical through market-approved. 

The firm invests in both private and public companies, targeting Chinese businesses as well as US- and Europe-based companies with strategic ties to the China market. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: , , , ,

Hot Investor Mandate: Corporate Venture Fund Seeks in Materials Science and Nutritional Health Companies Across the Globe

9 Sep

A corporate venture capital arm of a global science-based company invests in seed and venture stage companies, generally taking less than 25% ownership. While the firm has previously invested from seed through PIPE, the focus is on companies with products in development or early commercialization. Initial allocations typically range from a few hundred thousand dollars up to $5 million, with additional reserves for follow-on rounds. The firm is targeting approximately 5–10 investments in the next 6–9 months, and over 10 additional investments in the next 2 years. The investment scope is global, with a focus on the U.S., Europe, and Israel.

Within biomedical, the firm seeks materials science companies in orthopedics and soft tissue repair. In addition, the firm actively invests in human nutritional health, with a specific emphasis on personalized nutrition and companies developing nutritional products. This includes start-ups with digital or technology-driven models that enable personalization and precision.

The firm values experienced management teams and typically seeks a board seat, aiming to play an active role in portfolio companies. Strategic alignment with the parent company’s businesses is also an important consideration for investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: , , , ,

Hot Investor Mandate: Europe-Based Investment Firm Seeks Therapeutics and Medical Device Companies, Investing Up to €20M Over Company Lifecycle

9 Sep

An institutional alternative investor dedicated to direct investments in the life sciences has offices in Europe. The firm manages total assets under management to over EUR 1 billion. The firm invests EUR 5–20 million per portfolio company and expects to back approximately 20 companies from the current fund. It typically acts as a lead investor, providing equity capital and assuming a 20-40% ownership stake. While the firm primarily targets companies in Europe, around 30% of its portfolio is allocated to global opportunities. 

The firm invests in Therapeutics and Medical Devices. For therapeutics, the focus is on companies with proof of principle demonstrated in late preclinical studies or those in Phase I and beyond. For medical devices, companies must already have some in-human data to be considered. 

The firm seeks active involvement in portfolio management and typically holds board positions. Investment horizons generally range from 2–6 years, with exits often achieved through sales to larger companies positioned to complete commercialization. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: , , , ,

Hot Investor Mandate: Global VC Firm Focuses on Backing Innovations in Therapeutics, Diagnostics, and Digital Health Addressing Aging and Longevity

9 Sep

An investment firm with offices in US, Europe, and Asia typically makes investments from $500K–1.5M, and the firm invests globally. The focus is on innovations aimed at preventing age-associated diseases, extending healthy lifespan, and improving human and animal performance. 
 

Within life sciences, the firm invests primarily in therapeutics and diagnostics, and also considers digital health opportunities. Traditional medical devices are generally out of scope. Areas of interest include gene therapy, telomere attrition, proteostasis, regenerative medicine, personalized diagnostics/biomarkers, preventative therapies, cognitive enhancement, and related fields. The firm is modality-agnostic and stage-opportunistic. 
 

The firm seeks companies with strong, protectable IP with clear ownership, supported by diverse management teams with proven track records, and technologies demonstrating validated proof of concept. Investments undergo a three-step diligence process: initial review, additional review focusing on differentiators such as IP and business model, and final review. The firm is open to leading, co-leading, or co-investing and leverages a strong syndication network of like-minded investors. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: , , , ,

Genaxis, Silver Sponsor of RESI Boston, Hosts Exclusive Startup Showcase

9 Sep

By Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN

LSN is excited to announce Genaxis, a leading South Korea based accelerator and early-stage fund dedicated to deeptech and biotech innovation, as a Silver Sponsor of RESI Boston.

Genaxis is bringing five of Korea’s most innovative biotech and medtech startups to the global stage. These companies will be pitching at RESI Boston on September 17, 2025, where they will showcase breakthrough solutions spanning therapeutics, medical devices, digital health, and enabling technologies.

To provide an additional opportunity for investor engagement, Genaxis will also host an exclusive pre-RESI pitch session the day before the conference. The event will take place on Tuesday, September 16, 2025, 9:00 – 11:00am EST, at CIC Boston (50 Milk St, Boston, MA 02109).

At this session, 5 startups will each deliver a 6-minute pitch followed by a 7-minute Q&A, and active investors and strategic partners are invited to join. Please RSVP below if you are interested in meeting Genaxis and the pitching companies. Brief descriptions are provided below:

RSVP

Bilix, Inc. is a biotechnology company dedicated to developing innovative therapies for intractable diseases in inflammation and cancer, with the mission to improve human health one patient at a time for better and longer lives. Driven by courage and determination, Bilix takes on the challenge of finding cures for conditions long considered incurable. Our goal is to expedite drug development and provide therapeutic answers for patients in urgent need, while upholding a commitment to fairness and accessibility. By delivering cost-effective, equitable treatment solutions, Bilix strives to transform the lives of patients worldwide and bring hope where few options exist.

DeepsonBio is a company specialized in ultrasound devices for treating dementia. By utilizing a non-invasive method, we offer a safe and highly effective treatment for patients with Alzheimer’s dementia and normal pressure hydrocephalus dementia.

Our therapeutic ultrasound device is designed to improve cognitive function in patients with mild cognitive impairment (MCI) and early-stage Alzheimer’s disease, utilizing Multiple Low Intensity Pliant Ultrasound (M-LIPUS) for cerebrofluid stimulation.

Main Business Area:

  • Neurology
  • Neurodegenerative disease
  • Alzheimer’s disease
  • Normal pressure hydrocephalus

EXOSYSTEMS Inc. is a South Korea–based digital health company pioneering AI-driven neuromuscular biomarkers to transform how motor function is assessed, diagnosed, and monitored. Founded in 2017 as a spin-out from ETRI, EXOSYSTEMS develops integrated solutions that combine clinical-grade EMG/IMU sensors with advanced AI analytics to deliver objective, quantitative insights into muscle and motor performance.

Its flagship technologies include the Muscle Function Index (MFI), a digital biomarker platform designed to replace fragmented and subjective in-person motor assessments with standardized, high-resolution measures. These solutions serve both pharmaceutical companies, by providing validated digital endpoints for clinical trials, and hospitals and clinics, by enabling efficient point-of-care diagnostics and patient monitoring.

With $4M secured in VC funding, over $10M in national R&D grants, regulatory recognition from the Korean FDA, and validation studies with Roche Korea, EXOSYSTEMS is positioned to set a new global standard for neuromuscular digital health.

Laon Medi is a digital health company transforming orthodontics with software-driven workflows. Our flagship platform, Laon Ortho, solves the inefficiencies of clear aligner treatment planning, a process that traditionally requires hours of manual work and outsourced lab services. By automating case setup and integrating multimodal data such as CBCT and intraoral scans, Laon Ortho reduces planning time to minutes while allowing clinics to manage cases in-house. This shift improves margins, lowers patient costs, and accelerates adoption of clear aligner therapy. Laon Ortho is commercially deployed in dozens of clinics and labs across Korea, generating post-pilot revenues and validating scalability. The company is now expanding globally with a model that serves clinics, labs, and DSOs, positioning itself as a scalable digital dentistry platform with clear cost advantages and growing international demand.

RadaHaim, founded in 2022, is a biotechnology company pioneering standardized, scalable organoid platforms for drug discovery and toxicology testing. We have developed patient-derived and iPSC-derived liver organoids with consistent size and morphology, enabling reliable disease modeling and drug-induced liver injury (DILI) assays. Our preclinical service platform operates under GLP-inspired workflows, including batch-level QC, reference compound benchmarking, and high-content imaging analytics. By bridging the translational gap between animal studies and clinical outcomes, RadaHaim provides pharmaceutical and biotech partners with more predictive data to accelerate drug development and reduce failures in clinical trials. In addition to CRO services, our long-term goal is to commercialize assay kits that integrate standardized organoids with ready-to-use protocols. Based in Korea and now expanding into the U.S., RadaHaim aims to become a global leader in organoid-based NAMs (New Approach Methodologies) aligned with regulatory acceptance and the future of animal-free testing.

About Genaxis:

Genaxis is a leading accelerator dedicated to supporting deep-tech and biotech startups. We deliver customized acceleration programs, strategic mentoring, and global investor access to help companies grow beyond their local markets. With expertise in investment readiness, cross-border collaboration, and global market entry, Genaxis equips entrepreneurs with the tools and networks they need for sustainable growth. As a Silver Sponsor of RESI Boston 2025, we are committed to connecting innovative startups with global life science investors, fostering collaboration between Korea and the world. Our mission is to empower founders to achieve impactful innovation, create long-term value, and strengthen the global startup ecosystem.

Tags: , , , , , , , ,

Freedom to Operate: What It Is and Why Your Startup Can’t Afford to Ignore It 

9 Sep

By Michael J. Moedritzer, Associate, Polsinelli (Special Guest Contributor)

For biotech founders, intellectual property (IP) can make or break a company. The life sciences industry is driven by innovation, but it is also crowded with patents. While it’s essential to build your own IP portfolio, it is just as critical to ensure that your product will not infringe on someone else’s. Overlooking this risk can expose your startup to costly lawsuits that could derail your business before it has a chance to grow.

What is an FTO Opinion?
An FTO Opinion is a legal review by an IP attorney that determines whether your startup can develop, manufacture, and sell a product without infringing existing patents. The attorney analyzes relevant patents and applications in your target markets and provides guidance on whether changes to your design or a licensing agreement might be necessary.

Why Founders Need It
For founders, an FTO Opinion provides more than legal coverage. It gives you peace of mind that you are not unknowingly putting your company at risk. It can also provide protection if litigation arises, helping you defend against claims of willful infringement and limiting potential increased damages. Most importantly, it strengthens your credibility with investors and partners by showing that you have done the due diligence to safeguard your innovations.

Where to Start
Securing an FTO Opinion requires working with an experienced IP attorney, who will tailor the analysis to your product and market strategy. While it is an investment, it is one that could save your company millions and ensure that your innovation makes it to market.

Michael Moedritzer is an Associate in Polsinelli’s Intellectual Property department. He focuses his practice on domestic and international patent prosecution and works with clients to revise, analyze and evaluate intellectual property-related issues to provide comprehensive overview of the portfolio.

Tags: , , , , , , , , ,

← Older Entries
Newer Entries →